Japan’s FY2024 pharmaceutical sales revealed a sharp divergence among immune checkpoint inhibitors as MSD’s Keytruda (pembrolizumab) surged toward the 200-billion-yen…
HOME > TOP STORIES
TOP STORIES
-
ACADEMIA New Lung Cancer Guidelines to Give Keytruda Grade A Recommendation as First-Line Treatment
December 19, 2016
-
BUSINESS Fujifilm to Acquire Takeda’s Reagent Unit for 155 Billion Yen
December 16, 2016
-
BUSINESS Nippon Kayaku Introduces “MSLs” to Strengthen Detailing for Oncology Generics, Biosimilars, and Products in Development
December 16, 2016
-
ORGANIZATION JMA Wants Adjustment Rate as High as 5%: Yokokura
December 15, 2016
-
REGULATORY PD-L1 Expression Testing Won’t Be a Must for Opdivo, but Clarification Needed: Chuikyo
December 15, 2016
-
REGULATORY MHLW Drafts Optimal Use Guidelines for Opdivo in NSCLC
December 14, 2016
-
REGULATORY Survey Method, Product Scope for Annual Revisions to Be Discussed in 2017
December 14, 2016
-
BUSINESS Aspen Japan Starting on Right Foot on AG Biz: GSK Japan President
December 13, 2016
-
REGULATORY Chuikyo Reps, Distributors Fret Market Prices Will Be Kept High with Annual Revisions
December 12, 2016
-
REGULATORY (Update) “2%” Adjustment Rate Should Be Made a Discussion Point for Annual Revisions: Chuikyo Rep
December 12, 2016
-
REGULATORY Govt Eyes “Bailout Measures” for Products with Small NHI-Market Price Gaps in Annual Revision Plan
December 9, 2016
-
REGULATORY Shiozaki, Govt Panel Agree on Annual Price Reviews, but Scope of Drugs Still Unclear
December 8, 2016
-
BUSINESS Mitsubishi Tanabe Fending Off Inroads from Biosimilars through Add’l Indications for Remicade
December 8, 2016
-
REGULATORY LDP Tax Panel OKs Refit of R&D Tax Credit System in FY2017
December 7, 2016
-
BUSINESS Acquisition of Long-Listed Drugs to Promote Generic Sales; Sales Target of 50 Billion Yen “in Range”: Kyowa Pharm
December 7, 2016
-
ORGANIZATION Drug Pricing Policy Can’t Be Defined in 2-3 Weeks: PhRMA Exec
December 6, 2016
-
BUSINESS Chugai to Enter Hemophilia Field with Emicizumab; Peak Sales Could Top 200 Billion Yen
December 6, 2016
-
REGULATORY PM Abe’s Council to Discuss Annual Drug Price Revisions Again on Dec. 7
December 5, 2016
-
INTERVIEW Interview: Metgluco, AGs, and Diagnostics 3 Biz Pillars for New Sumitomo Dainippon Subsidiary
December 2, 2016
-
REGULATORY Industry, Healthcare Provider Reps Oppose “Annual Revisions” as Payers Hold Off Stance: Chuikyo
December 1, 2016
ページ
I recently attended a fantastic conference hosted by Prospection Japan, and one speaker, Dr. Joe Ledsam, really blew me away with his insights. He shared some truly fascinating developments about how AI is set to revolutionize healthcare, from how doctors…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…